Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy

Frontiers in Oncology

Volumn 3 JUN, Issue , 2013, Pages

  Pelzer, Uwe ^a   Hilbig, Andreas ^a   Sinns, Marianne ^a   Stieler, Jens ^a   Bahra, Marcus ^a   Dörken, Bernd ^a   Riess, Hanno ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CA 19 9; Pancreatic neoplasms; Prediction; Response; Therapy control

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT MONITORING; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 84891650434     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00155     Document Type: Article

References (20)

1. Ballehaninna, U. K., and Chamberlain, R. S. (2011). Serum CA 19-9 as a biomarker for pancreatic cancer-a comprehensive review. Indian J. Surg. Oncol. 2, 88-100. doi:10.1007/s13193-011-0042-1.
2. Burris, H. A. III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.
3. Conroy, T., Desseigne, F., and Ychou, M. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825. doi:10.1056/NEJMoa1011923.
4. Cunningham, D., Chau, I., and Stocken, D. D. (2009). Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513-5518. [Epub October 26, 2009]. doi:10.1200/JCO.2009.24.2446.
5. Duffy, M. J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V. L., Klapdor, R., et al. (2010). Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann. Oncol. 21, 441-447. doi:10.1093/annonc/mdp332.
6. Gillen, S., Schuster, T., Meyer Zum Büschenfelde, C., Friess, H., and Kleeff, J. (2010). Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7:e1000267. doi:10.1371/journal.pmed.1000267.
7. GLOBOCAN. (2008). International Agency for Research in Cancer. Section on Cancer Information. Available at: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 [accessed December12, 2010].
8. Heinemann, V., Boeck, S., and Hinke, A. (2008). Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82. doi:10.1186/1471-2407-8-82.
9. Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., et al. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 25, 2212-2217. doi:10.1200/JCO.2006.09.0886.
10. Ishii, H., Furuse, J., Nakachi, K., Suzuki, E., and Yoshino, M. (2005). Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. Jpn. J. Clin. Oncol. 35, 601-606. doi:10.1093/jjco/hyi151.
11. Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., and Fuhrer, P. (1979). Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 5, 957-971. doi:10.1007/BF01542654.
12. Lamerz, R. (1999). Role of tumour markers, cytogenetics. Ann. Oncol. 10(Suppl. 4), 145-149. doi:10.1093/annonc/10.suppl_4.S145.
13. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., et al. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23, 3509-3516. doi:10.1200/JCO.2005.06.023.
14. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2005). Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) (abstract). J. Clin. Oncol. 23, 1.
15. Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., et al. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200-1210. doi:10.1056/NEJMoa032295.
16. Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267-277. doi:10.1001/jama.297.3.267.
17. Pelzer, U. (2008a). First-line chemotherapy in advanced pancreatic cancer. Recent Results Cancer Res. 177, 57-60. [Review]. doi:10.1007/978-3-540-71279-4_7.
18. Pelzer, U. (2008b). Second-line chemotherapy in advanced pancreatic cancer. Recent Results Cancer Res. 177, 61-64. [Review]. doi:10.1007/978-3-540-71279-4_8.
19. Pelzer, U., Schwaner, I., and Stieler, J. (2011). Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer 47, 1676-1681. [Epub May 10, 2011]. doi:10.1016/j.ejca.2011.04.011.
20. Vormittag, L., Gleiss, A., Scheithauer, W., Lang, F., Laengle, F., and Kornek, G. V. (2009). Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. Oncology 77, 140-146. doi:10.1159/000229754.